Skip to main content
Top
Published in: Journal of Cardiovascular Translational Research 3/2019

01-06-2019 | Original Article

Long-Term Weight Gain Associated With High Omentin Levels at Hospital Discharge Improves Prognosis of Patients Following Acute Heart Failure

Authors: Rosa M. Agra-Bermejo, Rocio Gonzalez-Ferreiro, J. Nicolos Lopez-Canoa, Alfonso Varela-Roman, Ines Gomez-Otero, Sonia Eiras, José R. González-Juanatey

Published in: Journal of Cardiovascular Translational Research | Issue 3/2019

Login to get access

Abstract

A obesity paradox has been described following heart failure (HF). The aim of this study was to analyze the association between food intake-involved adipokines and long-term weight changes. Leptin, adiponectin, and omentin were analyzed in 92 acute HF (AHF) patients at discharge, classified on the basis of weight gains or losses > 6%. The mean follow-up was 256 ± 143 days. Leptin and adiponectin levels were similar among weight groups. However, omentin levels were higher in those patients who had gained weight (16 ± 5 ng/mL) than in those who had lost weight (12 ± 4 ng/mL) or showed no weight change (11 ± 5 ng/mL; p < 0.002). Omentin levels were the best independent predictors for patients with weight gain, who had less mortality and hospital readmission during the follow-up. The association between omentin levels and weight gain might explain part of the obesity paradox in HF.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983). Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation, 67, 968–977.CrossRef Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983). Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation, 67, 968–977.CrossRef
2.
go back to reference Horwich, T. B., Fonarow, G. C., Hamilton, M. A., MacLellan, W. R., Woo, M. A., & Tillisch, J. H. (2001). The relationship between obesity and mortality in patients with heart failure. Journal of the American College of Cardiology, 38, 789–795.CrossRefPubMed Horwich, T. B., Fonarow, G. C., Hamilton, M. A., MacLellan, W. R., Woo, M. A., & Tillisch, J. H. (2001). The relationship between obesity and mortality in patients with heart failure. Journal of the American College of Cardiology, 38, 789–795.CrossRefPubMed
3.
go back to reference Oreopoulos, A., Padwal, R., Kalantar-Zadeh, K., Fonarow, G. C., Norris, C. M., & McAlister, F. A. (2008). Body mass index and mortality in heart failure: A meta-analysis. American Heart Journal, 156, 13–22.CrossRefPubMed Oreopoulos, A., Padwal, R., Kalantar-Zadeh, K., Fonarow, G. C., Norris, C. M., & McAlister, F. A. (2008). Body mass index and mortality in heart failure: A meta-analysis. American Heart Journal, 156, 13–22.CrossRefPubMed
4.
go back to reference Uretsky, S., Messerli, F. H., Bangalore, S., et al. (2007). Obesity paradox in patients with hypertension and coronary artery disease. The American Journal of Medicine, 120, 863–870.CrossRefPubMed Uretsky, S., Messerli, F. H., Bangalore, S., et al. (2007). Obesity paradox in patients with hypertension and coronary artery disease. The American Journal of Medicine, 120, 863–870.CrossRefPubMed
5.
go back to reference Gonzalez-Cambeiro, M. C., Abu-Assi, E., Raposeiras-Roubin, S., et al. (2014). Exploring the obesity paradox in atrial fibrillation. AFBAR (atrial fibrillation Barbanza area) registry results. Journal of Atrial Fibrillation, 6, 991.PubMedPubMedCentral Gonzalez-Cambeiro, M. C., Abu-Assi, E., Raposeiras-Roubin, S., et al. (2014). Exploring the obesity paradox in atrial fibrillation. AFBAR (atrial fibrillation Barbanza area) registry results. Journal of Atrial Fibrillation, 6, 991.PubMedPubMedCentral
6.
go back to reference Farre, N., Aranyo, J., Enjuanes, C., et al. (2015). Differences in neurohormonal activity partially explain the obesity paradox in patients with heart failure: The role of sympathetic activation. International Journal of Cardiology, 181, 120–126.CrossRefPubMed Farre, N., Aranyo, J., Enjuanes, C., et al. (2015). Differences in neurohormonal activity partially explain the obesity paradox in patients with heart failure: The role of sympathetic activation. International Journal of Cardiology, 181, 120–126.CrossRefPubMed
7.
go back to reference Lavie, C. J., De Schutter, A., Alpert, M. A., Mehra, M. R., Milani, R. V., & Ventura, H. O. (2014). Obesity paradox, cachexia, frailty, and heart failure. Heart Failure Clinics, 10, 319–326.CrossRefPubMed Lavie, C. J., De Schutter, A., Alpert, M. A., Mehra, M. R., Milani, R. V., & Ventura, H. O. (2014). Obesity paradox, cachexia, frailty, and heart failure. Heart Failure Clinics, 10, 319–326.CrossRefPubMed
8.
go back to reference Nagarajan, V., Kohan, L., Holland, E., Keeley, E. C., & Mazimba, S. (2016). Obesity paradox in heart failure: A heavy matter. ESC Heart Failure, 3, 227–234.CrossRefPubMedPubMedCentral Nagarajan, V., Kohan, L., Holland, E., Keeley, E. C., & Mazimba, S. (2016). Obesity paradox in heart failure: A heavy matter. ESC Heart Failure, 3, 227–234.CrossRefPubMedPubMedCentral
9.
go back to reference Sandek, A., Anker, S. D., & von Haehling, S. (2009). The gut and intestinal bacteria in chronic heart failure. Current Drug Metabolism, 10, 22–28.CrossRefPubMed Sandek, A., Anker, S. D., & von Haehling, S. (2009). The gut and intestinal bacteria in chronic heart failure. Current Drug Metabolism, 10, 22–28.CrossRefPubMed
10.
go back to reference Khalid, U., Ather, S., Bavishi, C., et al. (2014). Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol, 64, 2743–2749.CrossRefPubMedPubMedCentral Khalid, U., Ather, S., Bavishi, C., et al. (2014). Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol, 64, 2743–2749.CrossRefPubMedPubMedCentral
11.
go back to reference Friedman, J. (2015). Leptin and the regulation of food intake and body weight. Journal of Nutritional Science and Vitaminology (Tokyo), 61(Suppl), S202.CrossRef Friedman, J. (2015). Leptin and the regulation of food intake and body weight. Journal of Nutritional Science and Vitaminology (Tokyo), 61(Suppl), S202.CrossRef
12.
go back to reference Brunetti, L., Orlando, G., Ferrante, C., et al. (2013). Orexigenic effects of omentin-1 related to decreased CART and CRH gene expression and increased norepinephrine synthesis and release in the hypothalamus. Peptides, 44, 66–74.CrossRefPubMed Brunetti, L., Orlando, G., Ferrante, C., et al. (2013). Orexigenic effects of omentin-1 related to decreased CART and CRH gene expression and increased norepinephrine synthesis and release in the hypothalamus. Peptides, 44, 66–74.CrossRefPubMed
13.
go back to reference Kubota, N., Yano, W., Kubota, T., et al. (2007). Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metabolism, 6, 55–68.CrossRefPubMed Kubota, N., Yano, W., Kubota, T., et al. (2007). Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metabolism, 6, 55–68.CrossRefPubMed
14.
go back to reference Fernandez-Trasancos, A., Agra, R. M., Garcia-Acuna, J. M., Fernandez, A. L., Gonzalez-Juanatey, J. R., & Eiras, S. (2017). Omentin treatment of epicardial fat improves its anti-inflammatory activity and paracrine benefit on smooth muscle cells. Obesity (Silver Spring), 25, 1042–1049.CrossRef Fernandez-Trasancos, A., Agra, R. M., Garcia-Acuna, J. M., Fernandez, A. L., Gonzalez-Juanatey, J. R., & Eiras, S. (2017). Omentin treatment of epicardial fat improves its anti-inflammatory activity and paracrine benefit on smooth muscle cells. Obesity (Silver Spring), 25, 1042–1049.CrossRef
15.
go back to reference Wolf, A. M., Wolf, D., Rumpold, H., Enrich, B., & Tilg, H. (2004). Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochemical and Biophysical Research Communications, 323, 630–635.CrossRefPubMed Wolf, A. M., Wolf, D., Rumpold, H., Enrich, B., & Tilg, H. (2004). Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochemical and Biophysical Research Communications, 323, 630–635.CrossRefPubMed
16.
go back to reference Sun, Y., Yang, Y., Qin, Z., et al. (2016). The acute-phase protein Orosomucoid regulates food intake and energy homeostasis via leptin receptor signaling pathway. Diabetes, 65, 1630–1641.CrossRefPubMed Sun, Y., Yang, Y., Qin, Z., et al. (2016). The acute-phase protein Orosomucoid regulates food intake and energy homeostasis via leptin receptor signaling pathway. Diabetes, 65, 1630–1641.CrossRefPubMed
17.
go back to reference Agra, R. M., Fernandez-Trasancos, A., Diaz-Rodriguez, E., et al. (2018). Nutrients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: Impact in de novo heart failure patients. International Journal of Medical Sciences, 15, 417–424.CrossRefPubMedPubMedCentral Agra, R. M., Fernandez-Trasancos, A., Diaz-Rodriguez, E., et al. (2018). Nutrients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: Impact in de novo heart failure patients. International Journal of Medical Sciences, 15, 417–424.CrossRefPubMedPubMedCentral
18.
go back to reference Ponikowski, P., Voors, A. A., Anker, S. D., et al. (2016). 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. European Heart Journal, 37, 2129–2200.CrossRefPubMed Ponikowski, P., Voors, A. A., Anker, S. D., et al. (2016). 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. European Heart Journal, 37, 2129–2200.CrossRefPubMed
19.
go back to reference Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., & Roth, D. (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Annals of Internal Medicine, 130, 461–470.CrossRefPubMed Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., & Roth, D. (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Annals of Internal Medicine, 130, 461–470.CrossRefPubMed
20.
go back to reference Anker, S. D., Negassa, A., Coats, A. J., et al. (2003). Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet, 361, 1077–1083.CrossRefPubMed Anker, S. D., Negassa, A., Coats, A. J., et al. (2003). Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet, 361, 1077–1083.CrossRefPubMed
21.
go back to reference Ignacio de Ulibarri, J., Gonzalez-Madrono, A., de Villar, N. G., et al. (2005). CONUT: A tool for controlling nutritional status. First validation in a hospital population. Nutrición Hospitalaria, 20, 38–45.PubMed Ignacio de Ulibarri, J., Gonzalez-Madrono, A., de Villar, N. G., et al. (2005). CONUT: A tool for controlling nutritional status. First validation in a hospital population. Nutrición Hospitalaria, 20, 38–45.PubMed
22.
go back to reference Kouris, N. T., Zacharos, I. D., Kontogianni, D. D., et al. (2005). The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. European Journal of Heart Failure, 7, 199–203.CrossRefPubMed Kouris, N. T., Zacharos, I. D., Kontogianni, D. D., et al. (2005). The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. European Journal of Heart Failure, 7, 199–203.CrossRefPubMed
23.
go back to reference Littnerova, S., Parenica, J., Spinar, J., et al. (2015). Positive influence of being overweight/obese on long term survival in patients hospitalised due to acute heart failure. PLoS One, 10, e0117142.CrossRefPubMedPubMedCentral Littnerova, S., Parenica, J., Spinar, J., et al. (2015). Positive influence of being overweight/obese on long term survival in patients hospitalised due to acute heart failure. PLoS One, 10, e0117142.CrossRefPubMedPubMedCentral
24.
go back to reference Yancy, C. W., Jessup, M., Bozkurt, B., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation, 128, 1810–1852.CrossRef Yancy, C. W., Jessup, M., Bozkurt, B., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation, 128, 1810–1852.CrossRef
25.
go back to reference McMurray, J. J., Adamopoulos, S., Anker, S. D., et al. (2012). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. European Journal of Heart Failure, 14, 803–869.CrossRefPubMed McMurray, J. J., Adamopoulos, S., Anker, S. D., et al. (2012). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. European Journal of Heart Failure, 14, 803–869.CrossRefPubMed
26.
go back to reference Pocock, S. J., McMurray, J. J., Dobson, J., et al. (2008). Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal, 29, 2641–2650.CrossRefPubMed Pocock, S. J., McMurray, J. J., Dobson, J., et al. (2008). Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal, 29, 2641–2650.CrossRefPubMed
28.
go back to reference Beck-da-Silva, L., Higginson, L., Fraser, M., Williams, K., & Haddad, H. (2005). Effect of orlistat in obese patients with heart failure: A pilot study. Congestive Heart Failure, 11, 118–123.CrossRefPubMed Beck-da-Silva, L., Higginson, L., Fraser, M., Williams, K., & Haddad, H. (2005). Effect of orlistat in obese patients with heart failure: A pilot study. Congestive Heart Failure, 11, 118–123.CrossRefPubMed
29.
go back to reference Mariotti, R., Castrogiovanni, F., Canale, M. L., Borelli, G., & Rondinini, L. (2008). Weight loss and quality of life in chronic heart failure patients. Journal of Cardiovascular Medicine (Hagerstown, Md.), 9, 576–580.CrossRef Mariotti, R., Castrogiovanni, F., Canale, M. L., Borelli, G., & Rondinini, L. (2008). Weight loss and quality of life in chronic heart failure patients. Journal of Cardiovascular Medicine (Hagerstown, Md.), 9, 576–580.CrossRef
30.
go back to reference Alpert, M. A., Terry, B. E., Mulekar, M., et al. (1997). Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. The American Journal of Cardiology, 80, 736–740.CrossRefPubMed Alpert, M. A., Terry, B. E., Mulekar, M., et al. (1997). Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. The American Journal of Cardiology, 80, 736–740.CrossRefPubMed
31.
go back to reference Zamora, E., Diez-Lopez, C., Lupon, J., et al. (2016). Weight loss in obese patients with heart failure. Journal of the American Heart Association, 5, e002468.CrossRefPubMedPubMedCentral Zamora, E., Diez-Lopez, C., Lupon, J., et al. (2016). Weight loss in obese patients with heart failure. Journal of the American Heart Association, 5, e002468.CrossRefPubMedPubMedCentral
32.
go back to reference Rossignol, P., Masson, S., Barlera, S., et al. (2015). Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: Insights from the GISSI-HF and Val-HeFT trials. European Journal of Heart Failure, 17, 424–433.CrossRefPubMed Rossignol, P., Masson, S., Barlera, S., et al. (2015). Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: Insights from the GISSI-HF and Val-HeFT trials. European Journal of Heart Failure, 17, 424–433.CrossRefPubMed
33.
go back to reference Lavie, C. J., Sharma, A., Alpert, M. A., et al. (2016). Update on obesity and obesity paradox in heart failure. Progress in Cardiovascular Diseases, 58, 393–400.CrossRefPubMed Lavie, C. J., Sharma, A., Alpert, M. A., et al. (2016). Update on obesity and obesity paradox in heart failure. Progress in Cardiovascular Diseases, 58, 393–400.CrossRefPubMed
34.
go back to reference Sharma, A., Lavie, C. J., Borer, J. S., et al. (2015). Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. The American Journal of Cardiology, 115, 1428–1434.CrossRefPubMed Sharma, A., Lavie, C. J., Borer, J. S., et al. (2015). Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. The American Journal of Cardiology, 115, 1428–1434.CrossRefPubMed
35.
go back to reference Ambrosy, A. P., Cerbin, L. P., Armstrong, P. W., et al. (2017). Body weight change during and after hospitalization for acute heart failure: Patient characteristics, markers of congestion, and outcomes: Findings from the ASCEND-HF trial. JACC Heart Failure, 5, 1–13.CrossRefPubMedPubMedCentral Ambrosy, A. P., Cerbin, L. P., Armstrong, P. W., et al. (2017). Body weight change during and after hospitalization for acute heart failure: Patient characteristics, markers of congestion, and outcomes: Findings from the ASCEND-HF trial. JACC Heart Failure, 5, 1–13.CrossRefPubMedPubMedCentral
36.
go back to reference Nunez, J., Nunez, E., Consuegra, L., et al. (2007). Carbohydrate antigen 125: An emerging prognostic risk factor in acute heart failure? Heart, 93, 716–721.CrossRefPubMed Nunez, J., Nunez, E., Consuegra, L., et al. (2007). Carbohydrate antigen 125: An emerging prognostic risk factor in acute heart failure? Heart, 93, 716–721.CrossRefPubMed
37.
go back to reference Nunez, J., Sanchis, J., Bodi, V., et al. (2010). Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. European Heart Journal, 31, 1752–1763.CrossRefPubMed Nunez, J., Sanchis, J., Bodi, V., et al. (2010). Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. European Heart Journal, 31, 1752–1763.CrossRefPubMed
38.
go back to reference Kovacic, D., Marinsek, M., Gobec, L., Lainscak, M., & Podbregar, M. (2008). Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clinical Research in Cardiology, 97, 24–31.CrossRefPubMed Kovacic, D., Marinsek, M., Gobec, L., Lainscak, M., & Podbregar, M. (2008). Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clinical Research in Cardiology, 97, 24–31.CrossRefPubMed
39.
go back to reference Barbosa-Ferreira, J. M., Fernandes, F., Dabarian, A., & Mady, C. (2013). Leptin in heart failure. Expert Opin Med Diagn, 7, 113–117.CrossRefPubMed Barbosa-Ferreira, J. M., Fernandes, F., Dabarian, A., & Mady, C. (2013). Leptin in heart failure. Expert Opin Med Diagn, 7, 113–117.CrossRefPubMed
40.
go back to reference Szabo, T., Scherbakov, N., Sandek, A., et al. (2013). Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis, 24, 50–56.CrossRefPubMed Szabo, T., Scherbakov, N., Sandek, A., et al. (2013). Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis, 24, 50–56.CrossRefPubMed
41.
go back to reference de Souza Batista, C. M., Yang, R. Z., Lee, M. J., et al. (2007). Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56, 1655–1661.CrossRefPubMed de Souza Batista, C. M., Yang, R. Z., Lee, M. J., et al. (2007). Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56, 1655–1661.CrossRefPubMed
42.
go back to reference Lafontan, M., & Viguerie, N. (2006). Role of adipokines in the control of energy metabolism: Focus on adiponectin. Current Opinion in Pharmacology, 6, 580–585.CrossRefPubMed Lafontan, M., & Viguerie, N. (2006). Role of adipokines in the control of energy metabolism: Focus on adiponectin. Current Opinion in Pharmacology, 6, 580–585.CrossRefPubMed
43.
go back to reference Agra, R. M., Teijeira-Fernandez, E., Pascual-Figal, D., et al. (2014). Adiponectin and p53 mRNA in epicardial and subcutaneous fat from heart failure patients. European Journal of Clinical Investigation, 44, 29–37.CrossRefPubMed Agra, R. M., Teijeira-Fernandez, E., Pascual-Figal, D., et al. (2014). Adiponectin and p53 mRNA in epicardial and subcutaneous fat from heart failure patients. European Journal of Clinical Investigation, 44, 29–37.CrossRefPubMed
44.
go back to reference Eiras, S., Varela-Roman, A., Andrade, M. C., et al. (2017). Non classical monocytes levels, increased by subcutaneous fat-Secretome, are associated with less Rehospitalization after heart failure admission. Journal of Cardiovascular Translational Research, 10, 16–26.CrossRefPubMed Eiras, S., Varela-Roman, A., Andrade, M. C., et al. (2017). Non classical monocytes levels, increased by subcutaneous fat-Secretome, are associated with less Rehospitalization after heart failure admission. Journal of Cardiovascular Translational Research, 10, 16–26.CrossRefPubMed
45.
go back to reference Watanabe, T., Watanabe-Kominato, K., Takahashi, Y., Kojima, M., & Watanabe, R. (2017). Adipose tissue-derived Omentin-1 function and regulation. Comprehensive Physiology, 7, 765–781.CrossRefPubMed Watanabe, T., Watanabe-Kominato, K., Takahashi, Y., Kojima, M., & Watanabe, R. (2017). Adipose tissue-derived Omentin-1 function and regulation. Comprehensive Physiology, 7, 765–781.CrossRefPubMed
46.
go back to reference von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009). Cardiac cachexia: A systematic overview. Pharmacology & Therapeutics, 121, 227–252.CrossRef von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009). Cardiac cachexia: A systematic overview. Pharmacology & Therapeutics, 121, 227–252.CrossRef
47.
go back to reference Ostman, J., Efendic, S., & Arner, P. (1969). Catecholamines and metabolism of human adipose tissue. I. Comparison between in vitro effects of noradrenaline, adrenaline and theophylline on lipolysis in omental adipose tissue. Acta Medica Scandinavica, 186, 241–246.CrossRefPubMed Ostman, J., Efendic, S., & Arner, P. (1969). Catecholamines and metabolism of human adipose tissue. I. Comparison between in vitro effects of noradrenaline, adrenaline and theophylline on lipolysis in omental adipose tissue. Acta Medica Scandinavica, 186, 241–246.CrossRefPubMed
48.
go back to reference Wedick, N. M., Mayer-Davis, E. J., Wingard, D. L., Addy, C. L., & Barrett-Connor, E. (2001). Insulin resistance precedes weight loss in adults without diabetes : The rancho Bernardo study. American Journal of Epidemiology, 153, 1199–1205.CrossRefPubMed Wedick, N. M., Mayer-Davis, E. J., Wingard, D. L., Addy, C. L., & Barrett-Connor, E. (2001). Insulin resistance precedes weight loss in adults without diabetes : The rancho Bernardo study. American Journal of Epidemiology, 153, 1199–1205.CrossRefPubMed
49.
go back to reference Uriel, N., Gonzalez-Costello, J., Mignatti, A., et al. (2014). Adrenergic activation, fuel substrate availability, and insulin resistance in patients with congestive heart failure. JACC Heart Failure, 1, 331–337.CrossRef Uriel, N., Gonzalez-Costello, J., Mignatti, A., et al. (2014). Adrenergic activation, fuel substrate availability, and insulin resistance in patients with congestive heart failure. JACC Heart Failure, 1, 331–337.CrossRef
Metadata
Title
Long-Term Weight Gain Associated With High Omentin Levels at Hospital Discharge Improves Prognosis of Patients Following Acute Heart Failure
Authors
Rosa M. Agra-Bermejo
Rocio Gonzalez-Ferreiro
J. Nicolos Lopez-Canoa
Alfonso Varela-Roman
Ines Gomez-Otero
Sonia Eiras
José R. González-Juanatey
Publication date
01-06-2019
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 3/2019
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-018-9840-y

Other articles of this Issue 3/2019

Journal of Cardiovascular Translational Research 3/2019 Go to the issue